Acumen Pharmaceuticals to Participate in the Bank of America Healthcare Conference
Acumen Pharmaceuticals (NASDAQ: ABOS), a clinical-stage biopharmaceutical company focused on developing treatments for Alzheimer's disease, has announced its participation in the upcoming Bank of America Healthcare Conference. The company's management will engage in a fireside chat scheduled for Wednesday, May 14, 2025, at 8:15 a.m. PT/11:15 a.m. ET. Investors and interested parties can access the live webcast through the Investors section of Acumen's website at www.acumenpharm.com, where the recording will remain available for 90 days.
Acumen Pharmaceuticals (NASDAQ: ABOS), un'azienda biofarmaceutica in fase clinica focalizzata sullo sviluppo di trattamenti per il morbo di Alzheimer, ha annunciato la sua partecipazione alla prossima Bank of America Healthcare Conference. Il management della società parteciperà a una conversazione informale prevista per mercoledì 14 maggio 2025, alle 8:15 PT/11:15 ET. Investitori e interessati potranno seguire la diretta streaming nella sezione Investor del sito web di Acumen, www.acumenpharm.com, dove la registrazione resterà disponibile per 90 giorni.
Acumen Pharmaceuticals (NASDAQ: ABOS), una compañía biofarmacéutica en etapa clínica centrada en desarrollar tratamientos para la enfermedad de Alzheimer, ha anunciado su participación en la próxima Conferencia de Salud de Bank of America. La dirección de la empresa participará en una charla informal programada para el miércoles 14 de mayo de 2025 a las 8:15 a.m. PT/11:15 a.m. ET. Inversionistas e interesados podrán acceder a la transmisión en vivo a través de la sección de Inversores en el sitio web de Acumen, www.acumenpharm.com, donde la grabación estará disponible durante 90 días.
Acumen Pharmaceuticals (NASDAQ: ABOS)는 알츠하이머병 치료제 개발에 주력하는 임상 단계 바이오제약 회사로, 곧 열리는 뱅크 오브 아메리카 헬스케어 컨퍼런스에 참여한다고 발표했습니다. 회사 경영진은 2025년 5월 14일 수요일 오전 8시 15분 PT/오전 11시 15분 ET에 예정된 화상 대화에 참여할 예정입니다. 투자자 및 관심 있는 분들은 Acumen 웹사이트(www.acumenpharm.com)의 투자자 섹션을 통해 생중계에 접속할 수 있으며, 녹화 영상은 90일간 제공됩니다.
Acumen Pharmaceuticals (NASDAQ : ABOS), une société biopharmaceutique en phase clinique spécialisée dans le développement de traitements contre la maladie d'Alzheimer, a annoncé sa participation à la prochaine conférence Healthcare de Bank of America. La direction de l'entreprise participera à une discussion informelle prévue le mercredi 14 mai 2025 à 8h15 PT/11h15 ET. Les investisseurs et les intéressés pourront accéder à la diffusion en direct via la section Investisseurs du site web d'Acumen, www.acumenpharm.com, où l'enregistrement restera disponible pendant 90 jours.
Acumen Pharmaceuticals (NASDAQ: ABOS), ein biopharmazeutisches Unternehmen in der klinischen Phase, das sich auf die Entwicklung von Behandlungen für Alzheimer konzentriert, hat seine Teilnahme an der bevorstehenden Bank of America Healthcare Conference angekündigt. Das Management des Unternehmens wird an einem Fireside Chat teilnehmen, der für Mittwoch, den 14. Mai 2025, um 8:15 Uhr PT/11:15 Uhr ET geplant ist. Investoren und Interessierte können den Live-Webcast über den Investor-Bereich auf der Website von Acumen unter www.acumenpharm.com verfolgen, wo die Aufzeichnung für 90 Tage verfügbar bleibt.
- None.
- None.
NEWTON, Mass., May 07, 2025 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers for the treatment of Alzheimer’s disease, announced today that management will participate in in a fireside chat at the Bank of American Healthcare Conference on Wednesday, May 14, 2025, at 8:15 a.m. PT/11:15 a.m. ET.
The live webcasts may be accessed under the Investors tab on www.acumenpharm.com and will be archived for 90 days.
About Acumen Pharmaceuticals, Inc.
Acumen Pharmaceuticals is a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer’s disease (AD). Acumen’s scientific founders pioneered research on AβOs, which a growing body of evidence indicates are early and persistent triggers of Alzheimer’s disease pathology. Acumen is currently focused on advancing its investigational product candidate, sabirnetug (ACU193), a humanized monoclonal antibody that selectively targets toxic soluble AβOs, in its ongoing Phase 2 clinical trial ALTITUDE-AD (NCT06335173) in early symptomatic Alzheimer’s disease patients, following positive results in its Phase 1 trial INTERCEPT-AD. The company is headquartered in Newton, Mass. For more information, visit www.acumenpharm.com.
Investors:
Alex Braun
abraun@acumenpharm.com
Media:
AcumenPR@westwicke.com
FAQ
When is Acumen Pharmaceuticals (ABOS) presenting at the Bank of America Healthcare Conference 2025?
What is Acumen Pharmaceuticals (ABOS) developing for Alzheimer's disease?
How can investors access Acumen Pharmaceuticals' (ABOS) presentation at the Bank of America Healthcare Conference?
What stage of development is Acumen Pharmaceuticals (ABOS)?
